Pediatric Neuroinflammatory and Neuropsychiatric Syndromes Associated with Dupilumab Treatment for Atopic Dermatitis.
Dupilumab treatment in pediatric patients may be associated with neuroinflammatory syndromes, and clinicians should monitor for behavioral changes and other neurological symptoms.
Where it sits
this study against the rest of the kpv corpusSummary and findings
This study reports on neuroinflammatory syndromes observed in 4 children undergoing Dupilumab treatment for atopic dermatitis. Symptoms included behavioral changes and neurodiagnostic abnormalities, with some improvement noted after treatment discontinuation. The study highlights potential neurological risks associated with this therapy in pediatric patients.
Abstract
Dupilumab, a monoclonal antibody blocking interleukin-4/interleukin-13 signaling, was associated with neuroinflammatory syndromes in 4 children treated for atopic dermatitis. Individuals exhibited behavioral changes, language impairment, and neurodiagnostic abnormalities 2-6 months after treatment initiation. Three improved with drug discontinuation and immunomodulatory therapy; 1 with pre-existing X-linked adrenoleukodystrophy required stem cell transplantation.